Loading…
Employees: 334
Size BioNote (377740.KS) is a South Korea Health Care company (Medical Specialties) with a market value of $343M, the 434th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩4,620 on 6 Nov 2026.
Performance Over six months the shares fell 9.6%, against -6.8% for the median peer and -24.5% for the South Korea market (cap-weighted) — 10th lowest of 20 in its peer set.
Growth Revenue grew 12.8% over the last twelve months (peer median +5.3%); the operating margin is 16.3% (peer median 3.4%).
Valuation It trades at 15.0× forward earnings against a peer median of 16.0× (3rd cheapest of 9).
Price implies For today's price to make sense, revenue must grow about -20% a year for seven years (Req g). Recent delivered growth is -28%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.2 points below its cost of capital (5.5% WACC).
Next results Next results expected around 12 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩126B | ₩118B | ₩103B | ₩90.1B | ₩480B |
| Revenue growth | — | +15% | +14% | -81% | — |
| Gross profit | ₩68.3B | ₩63.0B | ₩49.3B | -₩13.4B | ₩340B |
| EBITDA | ₩30.5B | ₩26.0B | ₩20.0B | -₩39.0B | ₩302B |
| Net income | -₩126B | -₩87.5B | ₩55.3B | -₩20.5B | ₩308B |
| Free cash flow | ₩41.6B | ₩6.27B | ₩47.5B | -₩8.16B | ₩207B |
| Capital expenditure | ₩4.07B | ₩8.27B | ₩10.5B | ₩4.54B | ₩42.5B |
| Total debt | ₩3.21B | ₩3.65B | ₩3.93B | ₩4.93B | ₩1.36B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 377740.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.7% | -5.6% | 9th highest of 21 |
| 6-month return | -9.6% | -6.8% | 10th lowest of 20 |
| Distance from 52-week high | -26.2% | -30.0% | 9th highest of 21 |
| Revenue growth (TTM) | +12.8% | +5.3% | 8th highest of 21 |
| Operating margin | 16.3% | 3.4% | 6th highest of 21 |
| Forward P/E | 15.0× | 16.0× | 3rd cheapest of 9 |
| Growth the price implies (Req g, 7 yrs) | -19.8% | 2.2% | 2nd least demanding of 11 |
| Growth delivered (Del g) | -28.5% | -0.4% | lowest of 11 |
| Hurdle (Req g minus delivered) | +8.7 pp | -10.8 pp | 4th most demanding of 11 |
| ROIC minus cost of capital | -4.2 pp | -3.7 pp | 9th lowest of 18 |
| EV / EBITDA | 3.3× | 11.4× | cheapest of 11 |
| Net debt / EBITDA | -12.0× | 1.3× | least indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| BioNote 377740.KS | South Korea | $343M | -10% | +13% | 16% | 15.0× | -19.8% | -28.5% |
| Chemclin Diagnostics 688468.SS | China | $342M | -23% | -14% | 6% | n/a | 31.9% | -4.5% |
| Orchestra BioMed OBIO | United States | $341M | +41% | +986% | -181% | n/a | n/a | n/a |
| Stratec SBS.DE | Germany | $341M | +41% | -3% | 3% | 16.4× | n/a | n/a |
| Peijia Medical 9996.HK | Hong Kong | $340M | -34% | +21% | -13% | 335.5× | n/a | n/a |
| ACRO Biomedical 6748.TWO | Taiwan | $347M | +129% | +45% | -178% | n/a | n/a | n/a |
| CapsoVision CV | United States | $336M | -11% | +15% | -217% | n/a | n/a | n/a |
| Jiangsu Nanfang Medical 603880.SS | China | $336M | +4% | -7% | -15% | n/a | 22.5% | -10.9% |
| Embecta EMBC | United States | $351M | +70% | -8% | 26% | 3.9× | -19.9% | -0.1% |
| Shenzhen Bioeasy Biotechnology 300942.SZ | China | $352M | -27% | +12% | -2% | n/a | n/a | n/a |
| Chongqing Xishan Science and Technology 688576.SS | China | $356M | -26% | -23% | -29% | 15.2× | n/a | n/a |
| COLTENE CLTN.SW | Switzerland | $361M | +3% | -2% | 8% | 25.9× | 0.1% | -0.7% |
| IVF HARTMANN VBSN.SW | Switzerland | $364M | -5% | +7% | 14% | n/a | -12.7% | -1.3% |
| Tauns Laboratories 197A.T | Japan | $322M | -2% | -23% | 29% | 15.5× | n/a | n/a |
| Kontour (Xi'an) Medical Technology 688314.SS | China | $321M | -39% | +4% | 27% | n/a | 6.1% | +16.4% |
| Surgical Science Sweden SUS.ST | Sweden | $321M | +86% | +8% | 16% | 27.8× | 4.3% | +56.8% |
| Japan Eyewear 5889.T | Japan | $321M | -7% | +15% | 32% | 10.7× | -9.0% | +20.2% |
| Orthofix Medical OFIX | United States | $321M | -32% | +3% | -4% | n/a | n/a | n/a |
| Star Sports Medicine 1609.HK | Hong Kong | $367M | -76% | +23% | 37% | n/a | -13.2% | +36.8% |
| Improve Medical Instruments 300030.SZ | China | $320M | -17% | -2% | 4% | n/a | 26.0% | -11.9% |
| Mobia Medical MOBI | United States | $373M | n/a | +105% | -145% | n/a | n/a | n/a |